Cerenome (PSTV) Income from Continuing Operations (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly Income from Continuing Operations of 6946000.0 for Q1 2026, down 70.12% year-over-year from 23246326.23 in Q1 2025, and down 32.86% quarter-over-quarter from 5228000.0 in Q4 2025.
Cerenome (PSTV) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Income from Continuing Operations for 16 consecutive years, with 6946000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 70.12% year-over-year to 6946000.0; the TTM figure through Mar 2026 stood at 18109103.0 (down 16.71% YoY), while the FY2025 annual figure was 41092000.0, down 11.07% from the prior year.
- Income from Continuing Operations fell to 6946000.0 in Q1 2026 per PSTV's latest filing, from 5228000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1511000.0 in Q2 2025 and bottomed at 6946000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 4227241.35 across 5 years, with a median of 4083000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 89.32% — and 2025, when it surged 58.68%.
- Plus Therapeutics' Income from Continuing Operations stood at 5658000.0 in 2022, then jumped by 30.06% to 3957000.0 in 2023, then retreated by 0.91% to 3993000.0 in 2024, then slumped by 30.93% to 5228000.0 in 2025, then plunged by 32.86% to 6946000.0 in 2026.
- Business Quant data shows PSTV's Income from Continuing Operations at 6946000.0 in Q1 2026, 5228000.0 in Q4 2025, and 4424103.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | -9.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.95 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -4.42 Mn |
| Jun 30, 2025 | -1.51 Mn |
| Mar 31, 2025 | -4.08 Mn |
| Dec 31, 2024 | -3.99 Mn |
| Sep 30, 2024 | -3.78 Mn |
| Jun 30, 2024 | -3.66 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Dec 31, 2023 | -3.96 Mn |
| Sep 30, 2023 | -3.22 Mn |
| Jun 30, 2023 | -2.73 Mn |
| Mar 31, 2023 | -4.77 Mn |
| Dec 31, 2022 | -5.66 Mn |
| Sep 30, 2022 | -5.22 Mn |
| Jun 30, 2022 | -5.30 Mn |
| Mar 31, 2022 | -4.12 Mn |
| Dec 31, 2021 | -3.44 Mn |
| Sep 30, 2021 | -3.69 Mn |
| Jun 30, 2021 | -2.80 Mn |